Ongoing hostilities and violence across the world leave people with diabetes in crisis and without access to essential resources. What can be done to help?

Explore the profound issue of diabetes stigma and steps we can take to combat it. From the Language Matters movement to personal stories and global pledges, discover how...

This trial is investigating a new oral medication, INV-202, which is designed to improve regulation in the kidney, liver, and pancreas.

Determining ideal carbohydrate intake for those with type 1 diabetes remains complex. Two studies at EASD 2023 highlight the benefits of a plant-based diet and...

Data presented at EASD 2023 reveals orforglipron's potential in type 2 diabetes management. The new oral GLP-1 medication demonstrated significant reductions for A1C and...

People with type 1 diabetes face higher kidney risks, yet treatments approved for type 2 aren't FDA approved for them due to clinical trial gaps. The EASD 2023 panel...

A third patient with type 1 diabetes becomes insulin-independent after VX-880 stem cell treatment. Presented at the 2023 EASD conference, Vertex's early-phase trial...

Despite advancements in diabetes treatment, emergency department visits among adults with diabetes surged 21% from 2014-2018. The 2023 EASD Conference unveils updated...

Survodutide, a GLP-1/glucagon dual receptor agonist, shows promising weight loss results in a clinical trial. The injectable medication, developed by Zealand and...

Experts addressed rising rates of cardiovascular disease in children with diabetes at EASD 2023, emphasizing prevention and finding new biomarkers for early...

New research from the ReTUNE study of people with type 2 diabetes at a normal weight by Dr. Roy Taylor, University of Newcastle, found that type 2 diabetes is not caused...

The newest study of once-weekly insulins showed that insulin icodec led to similar reductions in A1C and similar time in range compared to once-daily Tresiba (degludec).

Here are our top stories from September 2023. This month’s best stories cover a wide variety of topics like upcoming therapies, new research findings, and more.

Early research finds that people with type 1 diabetes who started taking Ozempic (semaglutide) were able to reduce their insulin dose. This research suggests potential...

Explore the link between diabetes & IBD: symptoms, treatment & guidance for a healthier life. Learn how to manage both conditions effectively in this article.

Discover the importance of 504 Plans and IEPs for students with diabetes in schools. Learn how to set up these support plans effectively.

Join a study at UC San Diego investigating the potential benefits of the GLP-1 agonist semaglutide in non-alcoholic fatty liver disease (NAFLD).

Explore the reasons behind the heightened risk of type 2 diabetes in the Hispanic community and find expert tips for prevention and management.

Combat diabetes stigma and bullying at school by educating, planning, and seeking community support for a more inclusive environment.

Manage diabetes to prevent nerve damage in hands and feet. Learn the connection between diabetes and neuropathy and ways to lower your risk.